Svein Lien appointed new CEO of Biotec Pharmacon ASA

12-Mar-2010 - Norway

Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.

Svein Lien (55) joins the company with a financial background and extensive experience from technology- and diagnostics businesses, most recently as CEO of Axis-Shield plc, the diagnostic company listed in London and Oslo.

"I am very much looking forward to this challenge" Svein Lien says. "I know the company very well from several years as a Board Member and have always been very confident with the technology platform and admired the highly skilled and talented organization. I also have a strong faith in the opportunities created by the close relation to the research community in Tromsø. We will need some more time to conclude on the roote cause behind the disappointing Phase III results and to clarify the strategic route forward. Following that we will inform the market, most likely via a capital market day in Q2."

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Last viewed contents

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

TranScrip Partners appoints David Oxlade as Chairman of the Board

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Excellent early results in large OvPlex ovarian cancer biomarker study

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board

Amorfix A(4) Assay Provides New Insights Into Alzheimer's Disease Pre-clinical Development Mouse Models - Amorfix Quantifies Rate of Accumulation of Amyloid in Seven Mouse Models of AD